trial

Ethyl-EPA Treatment of Prodromal Patients

NCTId NCT00634361
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 7 (actual)
Sponsored by Yale University
Primary completion 2005-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
7 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2001-09
Primary completion
2005-08
Eligibility
ALL · 14 Years · 35 Years

Interventions & indications

Drugs
ethyl-eicosapentaenoic acid

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Scott W. Woods, MDPrincipal Investigator

Sites

0 total

Linked catalysts

1
Ethyl-EPA Treatment of Prodromal Patients — primary completion2005-08

Facts & assertions

4 sourced
Enrollment
7
Phase
PHASE2,PHASE3
Primary Completion Date
2005-08
Status
COMPLETED
relationships
The graph out of here
drug
ethyl-eicosapentaenoic acid
drug
lead_sponsor
Yale University
company
indication
Schizophrenia Prodrome
indication
investigator
Scott W. Woods, MD
person